SAN DIEGO, CA, September 1, 2021 —SMSbiotech, Inc. announced today their collaboration with Acculab Life Sciences for the advancement of the research and development of the SMSbiotech stem cell based platform. The collaboration will advance a cell therapy that will target lung diseases. Acculab Life Sciences is a Contract Research Organization, located in the Sorrento Valley area of San Diego, CA, has USDA-approved, AAALAC accredited facilities which includes two sterile surgical suites, post-surgical recovery rooms and radiology and diagnostic laboratories.
“We believe this partnership will greatly benefit our advancement in the treatment of lung diseases such as COPD, Lung Fibrosis, IPF, and possibly COVID-19 long haul symptoms. These diseases affect such a large portion of the population which is why it is so important that we continue to push forward for treatments that can improve the quality of life for both the patients and their loved ones” says Richard Borror, CEO of SMSbiotech.
The collaboration between SMSbiotech and Acculab began in August 2021.
SMSbiotech Inc. is an early-stage C-Corp based in San Marcos, California. SMSbiotech’s vision is to build a new generation of effective biotherapies that are affordable and available to the masses, utilizing its unique platform technology.
About Platform Technology of SMSbiotech
SMSbiotech has developed a proprietary technology for manufacturing allogeneic SMS cells and derivatives at industrial scale. SMS cells are human adult stem cells with unique characteristics that make them conducive to large scale, therapeutic applications. This technology will address diverse indications related to regenerative medicine.
Richard Borror, CEO
Abdulkader Rahmo, CSO